SPYRE THERAPEUTICS, INC. Revenue
SPYRE THERAPEUTICS, INC. (SYRE) reported Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $0.00.
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $0.00.
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $0.00.
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $886.00K, a 61.96% decline from fiscal 2022.
- SPYRE THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $2.33M, a 87.57% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $688.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $688.00K derived: sum of 3 quarters · filed 2026-02-19 | $886.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 10-Q/A · filed 2024-11-18 | $688.00K derived: sum of 2 quarters · filed 2024-11-18 | $886.00K 10-Q/A · filed 2024-11-18 | $1.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $688.00K 10-Q/A · filed 2024-11-18 | $886.00K 10-Q/A · filed 2024-11-18 | $1.05M derived: sum of 3 quarters · filed 2025-02-27 | $1.23M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $198.00K 10-Q/A · filed 2024-11-18 | $366.00K derived: sum of 2 quarters · filed 2025-02-27 | $540.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.17M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $342.00K derived: sum of 2 quarters · filed 2025-02-27 | $967.00K derived: sum of 3 quarters · filed 2025-02-27 | $2.33M 10-K · filed 2025-02-27 |
| 2022-09-30 | $174.00K 10-Q · filed 2023-11-09 | $799.00K derived: sum of 2 quarters · filed 2023-11-09 | $2.16M 10-Q · filed 2023-11-09 | $5.80M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | $625.00K 10-Q · filed 2023-08-11 | $1.99M 10-Q · filed 2023-08-11 | $5.63M derived: sum of 3 quarters · filed 2024-11-18 | $7.03M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | $1.36M 10-Q · filed 2023-05-11 | $5.01M derived: sum of 2 quarters · filed 2024-11-18 | $6.41M derived: sum of 3 quarters · filed 2024-11-18 | $20.10M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | $3.64M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $5.04M derived: sum of 2 quarters · filed 2024-11-18 | $18.74M derived: sum of 3 quarters · filed 2024-11-18 | $18.74M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | $1.40M 10-Q · filed 2022-11-03 | $15.10M derived: sum of 2 quarters · filed 2022-11-03 | $15.10M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $13.70M 10-Q · filed 2022-08-04 | $13.70M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $0.00 derived: sum of 2 quarters · filed 2022-03-08 | $0.00 derived: sum of 3 quarters · filed 2022-03-08 | $0.00 10-K · filed 2022-03-08 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | $0.00 derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | $0.00 derived: sum of 3 quarters · filed 2019-08-06 | $0.00 derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 | $0.00 derived: sum of 2 quarters · filed 2019-05-07 | $0.00 derived: sum of 3 quarters · filed 2019-11-06 | $2.38M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $2.38M derived: sum of 3 quarters · filed 2020-02-24 | $3.89M 10-K · filed 2021-03-18 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-06 | $2.38M derived: sum of 2 quarters · filed 2020-02-24 | $3.89M 10-Q · filed 2019-11-06 | $5.37M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $2.38M 10-K · filed 2020-02-24 | $3.89M 10-Q · filed 2019-08-06 | $5.37M derived: sum of 3 quarters · filed 2020-02-24 | $6.63M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $1.51M 10-K · filed 2020-02-24 | $2.99M derived: sum of 2 quarters · filed 2020-02-24 | $4.25M derived: sum of 3 quarters · filed 2020-02-24 | $5.73M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $1.48M 10-K · filed 2019-03-07 | $2.74M derived: sum of 2 quarters · filed 2019-03-07 | $4.22M derived: sum of 3 quarters · filed 2019-03-07 | $5.21M 10-K · filed 2020-02-24 |
| 2017-09-30 | $1.26M 10-K · filed 2019-03-07 | $2.74M derived: sum of 2 quarters · filed 2019-03-07 | $3.72M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $1.48M 10-K · filed 2019-03-07 | $2.46M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $982.00K 10-K · filed 2019-03-07 | |||
| 2016-12-31 | $4.63M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |